Cancer Detection Software from serum Metabolome profile

OncoVeryx is intended to serve as a blood-based multi-cancer early detection (MCED) test. The test involves analysis of the untargeted metabolome profile of patient serum sample generated using liquid chromatography coupled to high-resolution mass spectrometry. The software integrated in OncoVeryx is used to identify metabolite signatures that describe the presence or absence of cancer, in case of positive cancer signature the software further analyzes the profile to designate the tissue of origin i.e. Cancer type. The intended use of OncoVeryx is as a complementary, and not a replacement, to existing methods that a healthcare provider may use to either screen for, or detect, cancer in patients. The benefits of OncoVeryx are that it detects many cancers for which screening tests do not currently exist and also detects them in the early stages to facilitate improved prognosis.